Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD

3.96  -0.03 (-0.75%)

Premarket: 3.77 -0.19 (-4.8%)

Fundamental Rating

6

BTMD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. BTMD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes BTMD very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BTMD was profitable.
BTMD had a positive operating cash flow in the past year.
BTMD had positive earnings in 4 of the past 5 years.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

The Return On Assets of BTMD (13.68%) is better than 95.90% of its industry peers.
BTMD has a Return On Invested Capital of 43.56%. This is amongst the best in the industry. BTMD outperforms 98.97% of its industry peers.
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROIC 43.56%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

Looking at the Profit Margin, with a value of 6.85%, BTMD belongs to the top of the industry, outperforming 85.13% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 16.78%, BTMD belongs to the best of the industry, outperforming 85.64% of the companies in the same industry.
In the last couple of years the Operating Margin of BTMD has declined.
BTMD's Gross Margin of 71.27% is fine compared to the rest of the industry. BTMD outperforms 80.00% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
BTMD has less shares outstanding than it did 1 year ago.
BTMD has a worse debt/assets ratio than last year.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 2.90 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a Altman-Z score of 2.90. This is in the better half of the industry: BTMD outperforms 74.87% of its industry peers.
The Debt to FCF ratio of BTMD is 4.81, which is a neutral value as it means it would take BTMD, 4.81 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BTMD (4.81) is better than 84.10% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Altman-Z 2.9
ROIC/WACC4.51
WACC9.66%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.42 indicates that BTMD should not have too much problems paying its short term obligations.
BTMD has a Current ratio of 1.42. This is in the lower half of the industry: BTMD underperforms 69.74% of its industry peers.
A Quick Ratio of 1.14 indicates that BTMD should not have too much problems paying its short term obligations.
The Quick ratio of BTMD (1.14) is worse than 72.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.14
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 490.91%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
BTMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.42%.
Measured over the past years, BTMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.38% on average per year.
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%

3.2 Future

The Earnings Per Share is expected to grow by 48.92% on average over the next years. This is a very strong growth
Based on estimates for the next years, BTMD will show a quite strong growth in Revenue. The Revenue will grow by 9.89% on average per year.
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

BTMD is valuated cheaply with a Price/Earnings ratio of 6.09.
Based on the Price/Earnings ratio, BTMD is valued cheaper than 96.41% of the companies in the same industry.
BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.34.
The Price/Forward Earnings ratio is 8.03, which indicates a very decent valuation of BTMD.
Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 86.15% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (21.03), we can say BTMD is valued rather cheaply.
Industry RankSector Rank
PE 6.09
Fwd PE 8.03
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 89.23% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 96.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.48
EV/EBITDA 7.44
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 49.45% in the coming years.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y49.45%

More info and screens

0

5. Dividend

5.1 Amount

BTMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTE CORP -A

NASDAQ:BTMD (6/20/2025, 8:19:14 PM)

Premarket: 3.77 -0.19 (-4.8%)

3.96

-0.03 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners66.3%
Inst Owner Change-7.92%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap200.42M
Analysts83.33
Price Target6.8 (71.72%)
Short Float %2.72%
Short Ratio4.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)228.05%
Min EPS beat(2)-1.96%
Max EPS beat(2)458.07%
EPS beat(4)2
Avg EPS beat(4)111.48%
Min EPS beat(4)-269.68%
Max EPS beat(4)458.07%
EPS beat(8)4
Avg EPS beat(8)19.41%
EPS beat(12)6
Avg EPS beat(12)-81.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.66%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)3
Avg Revenue beat(8)-1.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.05%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.74%
PT rev (3m)-10.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.14%
EPS NY rev (1m)4.57%
EPS NY rev (3m)7.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.91%
Valuation
Industry RankSector Rank
PE 6.09
Fwd PE 8.03
P/S 0.81
P/FCF 5.48
P/OCF 4.52
P/B N/A
P/tB N/A
EV/EBITDA 7.44
EPS(TTM)0.65
EY16.41%
EPS(NY)0.49
Fwd EY12.45%
FCF(TTM)0.72
FCFY18.26%
OCF(TTM)0.88
OCFY22.12%
SpS4.86
BVpS-1.78
TBVpS-2.07
PEG (NY)0.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROCE 55.13%
ROIC 43.56%
ROICexc 98.25%
ROICexgc 177.09%
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
FCFM 14.86%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Debt/EBITDA 3.22
Cap/Depr 210.54%
Cap/Sales 3.15%
Interest Coverage 4.43
Cash Conversion 98.57%
Profit Quality 216.82%
Current Ratio 1.42
Quick Ratio 1.14
Altman-Z 2.9
F-Score6
WACC9.66%
ROIC/WACC4.51
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)490.91%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%716.67%
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue 1Y (TTM)31.42%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%4.67%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
EBIT growth 1Y32.35%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y19.2%
FCF growth 1Y849.75%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y1512.04%
OCF growth 3Y10.29%
OCF growth 5Y12.28%